Dodging the magic bullet: understanding imatinib resistance.
Daley
George Q
GQ
Department of Biological Chemistry and Molecular Pharmacology; Harvard Medical School, Boston, Massachusetts 02142, USA. daley@wi.mh.edu
D001549:Benzamides; D001854:Bone Marrow Cells / Q000187:drug effects / Q000473:pathology / Q000502:physiology; D002869:Chromosome Aberrations; D019175:DNA Methylation / Q000187:drug effects*; D019008:Drug Resistance, Neoplasm; D016044:Fusion Proteins, bcr-abl / Q000235:genetics* / Q000378:metabolism*; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000473:pathology / Q000502:physiology*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D010879:Piperazines; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use; D014178:Translocation, Genetic
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl